51052-78-9

Basic information

• Product Name: 4-PIPERIDINEACETIC ACID HYDROCHLORIDE
• Synonyms: 4-PIPERIDINEACETIC ACID HCL;4-PIPERIDINEACETIC ACID HYDROCHLORIDE;PIPERIDINE-4-ACETIC ACID HYDROCHLORIDE;4-Piperidinylaceticacid;Pip-AcOH*HCl;2-(4-Piperidinyl)acetic acid;4-Piperidylacetic acid;4-piperidinylacetic acid(SALTDATA: HCl)
• CAS NO: 51052-78-9
• Molecular Formula: C₇H₁₃NO₂
• Molecular Weight: 179.64
• Product Categories: Carboxylic Acids;Pyrans, Piperidines &Piperazines;Miscellaneous;Carboxylic Acids;Pyrans, Piperidines & Piperazines
• Mol File: 51052-78-9.mol
• Article Data: 14

Chemical Properties

• Melting Point: 237-238 °C (decomp)
• Boiling Point: 286.818 °C at 760 mmHg
• Flash Point: 127.263 °C
• Appearance: /
• Density: 1.063 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.466
• PKA: 4.49±0.10(Predicted)
• CAS DataBase Reference: 4-PIPERIDINEACETIC ACID HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-PIPERIDINEACETIC ACID HYDROCHLORIDE(51052-78-9)
• EPA Substance Registry System: 4-PIPERIDINEACETIC ACID HYDROCHLORIDE(51052-78-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-41-37/38
• Safety Statements: 26-36-39
• HazardClass: IRRITANT
• Hazardous Substances Data: 51052-78-9(Hazardous Substances Data)

Usage

General Description

4-Piperidineacetic Acid Hydrochloride is a synthetic compound that falls under the category of Organic Salts and Derivatives. It has the molecular formula C7H14ClNO2 and is primarily known for its role in various biochemical and pharmaceutical applications. The chemical is characterized by its crystalline form and is highly soluble in water. However, it is strongly recommended that it should be stored in a dry and well-ventilated environment, away from heat and open flames, as it poses risks due to its corrosive nature as well as acute toxicity if ingested or inhaled. In addition, it may cause skin irritation or serious eye damage on contact. Therefore, appropriate protective measures should be taken while handling this chemical.

InChI:InChI=1/C7H13NO2/c9-7(10)5-6-1-3-8-4-2-6/h6,8H,1-5H2,(H,9,10)

Upstream product

• 102879-50-5 ethyl 4-pyridylacetate hydrochloride 
• 6622-91-9 2-(pyridine-4-yl)acetic acid hydrochloride 
• 28356-58-3 pyridine-4-acetic acid 
• 59184-90-6 ethyl (piperidin-4-yl)acetate 

Downstream Products

• 873967-82-9 (1-benzenesulfonyl-[4]piperidyl)-acetic acid 
• 157688-46-5 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)acetic acid 
• 196202-71-8 {1-[(E)-5-(4-Carbamimidoyl-phenyl)-2,2-dimethyl-3-oxo-pent-4-enoyl]-piperidin-4-yl}-acetic acid 
• 63845-28-3 2-(1-((benzyloxy)carbonyl)piperidin-4-yl)acetic acid 
• 622-26-4 4-(2-Hydroxyethyl)piperidine 
• 147699-19-2 tert-butyl 4-{2-[(methylsulfonyl)oxy]ethyl}piperidine-1-carboxylate 
• 202002-66-2 2-(piperidin-4-yl)acetonitrile 
• 184044-10-8 4-piperidineacetamide 
• 1613514-05-8 3,5-dichlorobenzyl 4-(2-((2-(1H-1,2,3-triazol-4-yl)ethyl)amino)-2-oxoethyl)piperidine-1-carboxylate 
• 1613514-07-0 3,5-dichlorobenzyl 4-(2-((2-(1-benzyl-1H-1,2,3-triazol-4-yl)ethyl)amino)-2-oxoethyl)piperidine-1-carboxylate 

Relevant articles and documents

Asymmetric hydrogenation of 3-alkylidene-2-piperidones using Noyori's catalyst. Effect of N-substituents on the enantioselectivity

The enantioselectivity in the asymmetric hydrogenation of 3-alkylidene-2-piperidones catalyzed by BINAP-Ru(II) complex was found to be significantly effected by the internal substituents on the lactam nitrogen, affording the corresponding 3-alkyl-2-piperidones in 52-92% ee.

PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS

The present invention provides pyridazine derivatives of formula (I), which are therapeutically useful as SMARCA2/4 degraders. These compounds are useful in the treatment and/or prevention of diseases or disorders dependent upon SMARCA2/4 in a mammal. The present invention also provides preparation of the compounds and pharmaceutical compositions comprising at least one of the pyridazine derivatives of formula (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof.

Discovery of Potent, Selective, and Orally Active Carboxylic Acid Based Inhibitors of Matrix Metalloproteinase-13

The matrix metalloproteinase enzyme MMP-13 plays a key role in the degradation of type II collagen in cartilage and bone in osteoarthritis (OA). An effective MMP-13 inhibitor would therefore be a novel disease modifying therapy for the treatment of arthritis. Our efforts have resulted in the discovery of a series of carboxylic acid inhibitors of MMP-13 that do not significantly inhibit the related MMP-1 (collagenase-1) or tumor necrosis factor-α (TNF-α) converting enzyme (TACE). It has previously been suggested (but not proven) that inhibition of the latter two enzymes could lead to side effects. A promising carboxylic acid lead 9 was identified and a convergent synthesis developed. This paper describes the optimization of 9 and the identification of a compound 24f for further development. Compound 24f is a subnanomolar inhibitor of MMP-13 (IC50 value 0.5 nM and Ki of 0.19 nM) having no activity against MMP-1 or TACE (IC50 of >10000 nM). Furthermore, in a rat model of MMP-13-induced cartilage degradation, 24f significantly reduced proteoglycan release following oral dosing at 30 mg/kg (75% inhibition, p 0.05) and at 10 mg/kg (40% inhibition, p 0.05).

Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides

The present invention relates to azacycloalkylalkanoyl peptides and pseudopeptides which inhibit platelet aggregation and thrombus formation thereby being useful in the prevention and treatment of thrombosis associated with disease states such as myocardial infarction, stroke, peripheral arterial disease, and disseminated intravascular coagulation, to methods for the prevention or treatment of thrombosis in a mammal in need of such therapy comprising the administration of a therapeutically effective amount of such compounds, and to pharmaceutical compositions comprising such compounds.